Clinical Brief: Advancements in Dyslipidemia Treatments and ASCVD Risk Reduction for High-Risk Individuals

Clinical Brief: Advancements in Dyslipidemia Treatments and ASCVD Risk Reduction for High-Risk Individuals is organized by Tarsus CNS.

Course Opens: 04/11/2025
Course Expires: 04/11/2026

Description:
The session, “Evolving Therapies in Dyslipidemia and ASCVD Risk Reduction: Putting It All Together in High-Risk Patients,” was presented by Dr. Pamela B. Morris, Professor of Medicine, Cardiology from The Medical University of South Carolina, Charleston, SC, supported by an educational grant from Esperion Therapeutics.

Dr. Morris discussed the latest advancements in managing dyslipidemia and reducing atherosclerotic cardiovascular disease (ASCVD) risk. This comprehensive discussion focused on high-risk patients and emphasized the integration of innovative lipid-lowering therapies, such as bempedoic acid, PCSK9 inhibitors, and combination treatments, alongside traditional statin use. She provided actionable insights to enhance patient care and lessen the burden of ASCVD.

Learning Objectives:
After completing this activity, the participant should be better able to:

• Identify patients at high or very high risk for atherosclerotic cardiovascular disease (ASCVD)
• Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk. 
• Illustrate how newer classes of drugs may help to overcome challenges with patient adherence or those experiencing difficulties meeting LDL-C targets.  
• Select individualized treatment strategies for LDL-C lowering that prioritize the early initiation and intensification of therapy to reduce ASCVD risk according to current guidelines and evidence.  
• Discuss strategies to implement patient-tailored care and shared-decision making while choosing the most adequate LLTs.